Protocol Number: 01-C-0011
Patients 18 years of age and older with malignant mesothelioma or cancer of the head, neck, lung, cervix or ovaries may be eligible for this study. Candidates will have a medical history, physical examination, blood and urine tests, electrocardiogram (EKG) and chest X-ray, and tumor evaluation with computerized tomography (CT) scans or other imaging tests. Participants will receive SS1(dsFv)-PE38 intravenously (through a vein) for 10 consecutive days. Weight and vital signs (temperature, heart and breathing rate and blood pressure) will be recorded and blood tests will be done during and after the treatment to look for side effects. Physical exams and blood and urine tests will be done to evaluate side effects weekly for two weeks, or more often if side effects occur. Depending on side effects, treatments may be repeated every 4 weeks for a maximum of four treatments. Physical examinations and blood and urine tests will be repeated with each treatment, and X-rays or CT scans will be done four weeks after each treatment to measure the effect of treatment on the tumor. An EKG will be repeated after three courses of treatment, or sooner if treatment is stopped. After the final treatment, follow-up visits will be scheduled at 3-month intervals.
Search The Studies | Help | Questions |
Warren Grant Magnuson Clinical Center (CC) |
||